| Revenue Growth | Total revenue $19.3M vs $8.6M YoY; product sales up 78.5% YTD. |
|---|---|
| Mgmt Confidence | High confidence in scaling; cited 'fourth consecutive quarterly on-target performance.' |
| Demand Visibility | Two new evaluation agreements signed; shifting from technical feasibility to deployment. |
| Margin Trends | Gross margin 74.5% in Q3; full-year 2026 guided to low 70s. |
| Op. Leverage | R&D and SG&A expenses declined YoY despite significant revenue growth. |
| Vol vs Price | Growth led by CDX049 enzyme volume and new product approvals. |
| Segment Growth | Biocatalysis business returning to growth; Ecosynthesis platform gaining innovator traction. |
| New Clients | Signed feasibility study with siRNA pioneer and evaluation with large biopharma. |
| Capex & Debt | $60M term loan; $42.5M drawn to replace debt; cash runway through 2028. |
| Regulatory | Successful FDA interaction regarding Ecosynthesis specifications and comparability arguments. |
| Commentary | Focusing on disrupting oligonucleotide manufacturing via 70% more capital-efficient enzymatic processes. |
| New Launches | Ecosynthesis 100-gram scale achieved; plans for 500-gram and kilo-scale readiness. |
Growth
Total revenue grew 124% to $19.3M; biocatalysis product sales rose 78.5% year-to-date.
Outlook
Reiterated 2026 revenue guidance of $72M-$76M; targeting 500-gram and kilo-scale production next.
Risks
Management pivoted on specific revenue phasing for new partnerships, citing dynamic funnel timing.
The company's earnings call, NASDAQ: CDXS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Codexis, Inc.: key numbers
- Share price
- $1.06Close, Nov 16
- Market cap
- $116M
- Shares outstanding
- 109.6MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Industrial Organic ChemicalsSIC 2860
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Codexis, Inc.
All →Codexis Q3 2026 Results: Net Loss of $8.13M, Loss Narrows
Codexis reported a significant increase in total revenues to $19.26 million for Q3 2026, up from $8.60 million in the prior year, driven primarily by product revenue growth. The company successfully reduced its quarterly net loss to $8.13 million compared to $19.62 million in Q3 2025, while strengthening its cash position through a $24.9 million net equity offering.
- Key figure
- Net loss $8.13M
Codexis Financial Results
Codexis reported Q3 2026 revenue of $19.3 million, a significant increase from $8.6 million in the prior year, driven by higher product revenue from new customer launches. The company also highlighted a new $60 million term loan facility with Trinity Capital and the successful scale-up of its ECO Synthesis Manufacturing Platform to 100-gram scale.
- Term
- Q3 2026
“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading innovators in the siRNA field.”
Alison Moore, PhD, President and Chief Executive Officer
“We have made significant progress in industrializing our technology while simultaneously increasing our revenue base, managing expenses, and improving the financial stability of our company.”
Alison Moore, PhD, President and Chief Executive Officer
Codexis $60M Debt Financing with Trinity Capital Inc.
Codexis entered into a $60 million Loan and Security Agreement with Trinity Capital, consisting of a $42.5 million initial tranche and $17.5 million in subsequent tranches. The debt is secured by substantially all company assets and carries a variable interest rate with an interest-only period extending up to November 2030. The facility provides capital to support operations while maintaining a financial covenant tied to the company's market capitalization.
- Value
- $60M
- Counterparty
- Trinity Capital Inc.
- Term
- 5 years